Skip to main content
. 2006 Aug;80(16):7799–7806. doi: 10.1128/JVI.00318-06

TABLE 5.

Comparison of anti-hMPV and anti-RSV monoclonals

Antibodya In vitro data
In vivo 2-log reduction data
Virus type kon(105 M−1 s−1) koff(10−4 M−1) Kd (nM) IC50 neutralization (μg/ml) Dose (mg/kg) Concn of IgG in serum (μg/ml)
MAb 234 A 7.83 3.52 4.49 1.2-0.6 1.0 8
B 1.92 4.63 2.41 0.2-0.01 1.0 6
MAb 338 A 1.58 2.76 1.74 0.8-0.4 1.0 5
B 1.92 2.72 1.42 0.2-0.03 0.3 4
Palivizumab A 1.27 4.3 3.39 0.453 2.5 ∼30
B NDb ND ND 0.06 2.5 ∼30
a

Data for the MAbs were derived from this publication. Data for palivizumab are from references 10 and 28 and personal communication from N. K. Patel.

b

ND, not determined.